| Summary of Financial Data for Company's Reportable Segment |
The following table presents certain financial data for the Company's reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Clinical trial expenses |
|
$ |
20,716 |
|
|
$ |
5,987 |
|
|
$ |
45,535 |
|
|
$ |
7,926 |
|
Employee-related research and development expenses |
|
|
16,836 |
|
|
|
6,958 |
|
|
|
32,829 |
|
|
|
14,008 |
|
Chemistry, manufacturing and controls expenses |
|
|
6,331 |
|
|
|
3,404 |
|
|
|
12,748 |
|
|
|
7,360 |
|
Preclinical program expenses |
|
|
8,294 |
|
|
|
9,727 |
|
|
|
13,816 |
|
|
|
15,808 |
|
Other research and development expenses |
|
|
1,258 |
|
|
|
770 |
|
|
|
2,191 |
|
|
|
1,531 |
|
Employee-related general and administrative expenses |
|
|
5,774 |
|
|
|
1,902 |
|
|
|
12,764 |
|
|
|
3,962 |
|
Professional fees and other general and administrative expenses |
|
|
4,339 |
|
|
|
1,915 |
|
|
|
8,168 |
|
|
|
3,611 |
|
Other segment items(1) |
|
|
(3,356 |
) |
|
|
(818 |
) |
|
|
(7,191 |
) |
|
|
(2,021 |
) |
Net loss |
|
$ |
60,192 |
|
|
$ |
29,845 |
|
|
$ |
120,860 |
|
|
$ |
52,185 |
|
(1)Other segment items include interest income and other income, net.
|